Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 21 | 2024 | 738 | 5.780 |
Why?
|
| Adenocarcinoma | 8 | 2023 | 1071 | 2.360 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2022 | 167 | 1.430 |
Why?
|
| Colorectal Neoplasms | 5 | 2024 | 652 | 1.210 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2017 | 316 | 0.850 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 1416 | 0.760 |
Why?
|
| Early Detection of Cancer | 3 | 2022 | 414 | 0.740 |
Why?
|
| Barrett Esophagus | 3 | 2014 | 358 | 0.710 |
Why?
|
| Emergency Service, Hospital | 3 | 2024 | 1156 | 0.710 |
Why?
|
| Ileitis | 1 | 2020 | 10 | 0.670 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 2020 | 8 | 0.670 |
Why?
|
| Diabetes Mellitus | 3 | 2024 | 937 | 0.610 |
Why?
|
| Intestinal Obstruction | 1 | 2020 | 97 | 0.600 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 481 | 0.590 |
Why?
|
| Veterans | 3 | 2024 | 1785 | 0.560 |
Why?
|
| Colonic Polyps | 1 | 2019 | 83 | 0.560 |
Why?
|
| Risk Factors | 14 | 2024 | 11182 | 0.530 |
Why?
|
| Crohn Disease | 1 | 2020 | 291 | 0.530 |
Why?
|
| Aspirin | 1 | 2017 | 231 | 0.500 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2018 | 757 | 0.500 |
Why?
|
| Coffee | 1 | 2015 | 30 | 0.460 |
Why?
|
| Proportional Hazards Models | 6 | 2023 | 1488 | 0.460 |
Why?
|
| Caffeine | 1 | 2015 | 70 | 0.450 |
Why?
|
| Gastric Balloon | 1 | 2014 | 3 | 0.440 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2014 | 15 | 0.440 |
Why?
|
| Air | 1 | 2014 | 26 | 0.430 |
Why?
|
| Mesenteric Ischemia | 1 | 2014 | 30 | 0.430 |
Why?
|
| Portal Vein | 1 | 2014 | 95 | 0.420 |
Why?
|
| Humans | 38 | 2024 | 134156 | 0.410 |
Why?
|
| Aged | 19 | 2024 | 21775 | 0.410 |
Why?
|
| United States | 9 | 2024 | 11763 | 0.400 |
Why?
|
| Device Removal | 1 | 2014 | 223 | 0.380 |
Why?
|
| Middle Aged | 20 | 2024 | 29399 | 0.370 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2012 | 67 | 0.370 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2012 | 93 | 0.370 |
Why?
|
| Hepatitis C, Chronic | 1 | 2015 | 373 | 0.340 |
Why?
|
| Feeding Behavior | 1 | 2015 | 732 | 0.310 |
Why?
|
| Body Composition | 2 | 2023 | 562 | 0.300 |
Why?
|
| Prevalence | 3 | 2024 | 2684 | 0.290 |
Why?
|
| Incidence | 4 | 2020 | 3416 | 0.280 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 947 | 0.270 |
Why?
|
| Mass Screening | 3 | 2022 | 840 | 0.270 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2024 | 710 | 0.270 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 1007 | 0.270 |
Why?
|
| Endoscopy, Digestive System | 3 | 2019 | 159 | 0.270 |
Why?
|
| Male | 20 | 2024 | 66127 | 0.240 |
Why?
|
| Case-Control Studies | 4 | 2017 | 3668 | 0.230 |
Why?
|
| Prospective Studies | 7 | 2021 | 6601 | 0.220 |
Why?
|
| Gastroenterologists | 1 | 2023 | 12 | 0.210 |
Why?
|
| Female | 17 | 2024 | 71928 | 0.210 |
Why?
|
| Risk Assessment | 3 | 2017 | 3743 | 0.180 |
Why?
|
| Cyst Fluid | 1 | 2021 | 6 | 0.180 |
Why?
|
| Adult | 10 | 2020 | 31945 | 0.180 |
Why?
|
| Survival Analysis | 4 | 2019 | 1599 | 0.180 |
Why?
|
| Pancreatic Cyst | 1 | 2021 | 28 | 0.180 |
Why?
|
| International Classification of Diseases | 1 | 2022 | 100 | 0.180 |
Why?
|
| Pancreas | 1 | 2022 | 232 | 0.180 |
Why?
|
| Logistic Models | 2 | 2023 | 1909 | 0.170 |
Why?
|
| Adipose Tissue | 2 | 2023 | 510 | 0.170 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 288 | 0.170 |
Why?
|
| Histamine H2 Antagonists | 1 | 2020 | 50 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 2198 | 0.160 |
Why?
|
| Survival Rate | 3 | 2020 | 2218 | 0.160 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 370 | 0.160 |
Why?
|
| Duodenal Diseases | 1 | 2019 | 34 | 0.160 |
Why?
|
| Proteome | 1 | 2021 | 281 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 79 | 0.150 |
Why?
|
| Jews | 1 | 2019 | 35 | 0.150 |
Why?
|
| Adenoma | 1 | 2020 | 143 | 0.150 |
Why?
|
| Diabetes Complications | 1 | 2020 | 206 | 0.150 |
Why?
|
| Lymph Nodes | 2 | 2019 | 399 | 0.150 |
Why?
|
| Syphilis | 1 | 2019 | 98 | 0.150 |
Why?
|
| Penicillins | 1 | 2019 | 155 | 0.150 |
Why?
|
| Neoplasms | 1 | 2014 | 3038 | 0.150 |
Why?
|
| Medical History Taking | 1 | 2019 | 118 | 0.150 |
Why?
|
| Leukocytes | 1 | 2019 | 223 | 0.140 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 7217 | 0.140 |
Why?
|
| Intestine, Small | 1 | 2020 | 317 | 0.140 |
Why?
|
| Protective Factors | 1 | 2017 | 92 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 680 | 0.140 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 566 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 1 | 2020 | 285 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2024 | 17540 | 0.130 |
Why?
|
| Muscle, Skeletal | 2 | 2023 | 1040 | 0.130 |
Why?
|
| Nurses | 1 | 2017 | 75 | 0.130 |
Why?
|
| Odds Ratio | 2 | 2017 | 1338 | 0.130 |
Why?
|
| Health Surveys | 1 | 2017 | 262 | 0.130 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 176 | 0.130 |
Why?
|
| Weight Loss | 1 | 2020 | 516 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1492 | 0.130 |
Why?
|
| Colonoscopy | 2 | 2020 | 249 | 0.130 |
Why?
|
| Epidemiological Monitoring | 1 | 2016 | 63 | 0.130 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 756 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 5477 | 0.120 |
Why?
|
| alpha-Fetoproteins | 1 | 2016 | 134 | 0.120 |
Why?
|
| Paris | 1 | 2015 | 11 | 0.120 |
Why?
|
| Liver Diseases | 1 | 2019 | 392 | 0.120 |
Why?
|
| Body Mass Index | 2 | 2020 | 1719 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 3506 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 625 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2020 | 5222 | 0.110 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 49 | 0.110 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2013 | 20 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 719 | 0.110 |
Why?
|
| Helicobacter pylori | 1 | 2023 | 1335 | 0.110 |
Why?
|
| Helicobacter Infections | 1 | 2023 | 1278 | 0.110 |
Why?
|
| Prognosis | 3 | 2019 | 5086 | 0.100 |
Why?
|
| Registries | 1 | 2020 | 1578 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 1 | 2013 | 155 | 0.100 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2014 | 244 | 0.100 |
Why?
|
| Smoking | 1 | 2018 | 1136 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2019 | 1099 | 0.090 |
Why?
|
| Health Status | 1 | 2014 | 412 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2014 | 245 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 1317 | 0.090 |
Why?
|
| Self Report | 1 | 2014 | 553 | 0.090 |
Why?
|
| Age of Onset | 1 | 2012 | 638 | 0.090 |
Why?
|
| Family | 1 | 2014 | 593 | 0.090 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2014 | 283 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 3114 | 0.070 |
Why?
|
| Time Factors | 1 | 2017 | 6610 | 0.070 |
Why?
|
| Pancreatectomy | 2 | 2018 | 152 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 3754 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 972 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 1626 | 0.060 |
Why?
|
| Mutation | 1 | 2018 | 6338 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2024 | 107 | 0.050 |
Why?
|
| Gastroscopy | 1 | 2023 | 100 | 0.050 |
Why?
|
| Cachexia | 1 | 2023 | 57 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 294 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 964 | 0.050 |
Why?
|
| Muscular Atrophy | 1 | 2023 | 90 | 0.050 |
Why?
|
| Metaplasia | 1 | 2023 | 219 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2024 | 827 | 0.040 |
Why?
|
| Abdominal Cavity | 1 | 2019 | 8 | 0.040 |
Why?
|
| Treponema pallidum | 1 | 2019 | 50 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2019 | 131 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2019 | 13074 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 837 | 0.040 |
Why?
|
| Telomere | 1 | 2019 | 231 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2017 | 59 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2024 | 804 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2018 | 141 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 134 | 0.030 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2017 | 106 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 453 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 843 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1304 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1506 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1765 | 0.030 |
Why?
|
| Occipital Lobe | 1 | 2013 | 34 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1979 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1595 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 240 | 0.020 |
Why?
|
| Liver | 1 | 2019 | 1879 | 0.020 |
Why?
|
| Child | 1 | 2012 | 25890 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1923 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 2137 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 1721 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2301 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2578 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 2771 | 0.020 |
Why?
|
| Obesity | 1 | 2014 | 2446 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3857 | 0.010 |
Why?
|